Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of KLT-1101 in advanced solid tumors
ChiCTR2000036309Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Bengbu Medical University
- Start
- Mar 2020
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of KLT-1101 in Nonhematologic neoplasms and triple-negative breast cancer (TNBC), sponsored by First Affiliated Hospital of Bengbu Medical University. Primary endpoint: Safety and tolerability. Planned start Mar 2020; status: not yet recruiting.
02
Drugs
KLT-1101
03
Conditions
Nonhematologic neoplasmstriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR2000036309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036309.